medigraphic.com
ISSN 0016-3813 (Print)

2006, Number 5

<< Back Next >>

Gac Med Mex 2006; 142 (5)

Recombinant factor VII activated in non-hemophiliac patients with acute severe hemorrhage in the intensive care unit.

Raúl Carrillo-Esper R, Sánchez-Zúñiga MJ, Elizondo-Argueta S, Visoso-Palacios P, Carrillo-Córdova JR

Language: Spanish
References: 25
Page: 369-376
PDF size: 336.28 Kb.


ABSTRACT

Background. Severe hemorrhage is a frequent complication with multiple etiologies and high morbi-mortality observed among critically ill patients. Recombinant Factor VIIa (rFVIIa) constitutes a new therapeutic alternative.
Objective. Analyze the evolution in a non-hemophiliac patient group with severe hemorrhage treated with rFVIIa.
Material and Methods. Ten non-hemophiliac patients with severe hemorrhage, five men and five women between 18 and 74 years, were included and treated with rFVIIa. We used a t test for statistic analyses. Significance was set at p‹0.001.
Results. Among patients treated with rFVIIa, hemorrhage was controlled and the use of blood products was significantly diminished (p‹ 0.001). Coagulation tests, fibrinogen levels, platelet count and perfusion parameters increased significantly (p‹ 0.001).
Conclusions. rFVIIa is a therapeutic alternative for the treatment of severe hemorrhage not controlled by conventional management.


REFERENCES

  1. Carrillo ER, Salmeron NP, Carvajal RR, Contreras DV, Hernández AC. Rompiendo el paradigma del modelo humoral al modelo celular de la coagulación. Aplicación clínica en el enfermo grave. Rev AMMCTI 2004;18:17-23.

  2. Hoffman M, Monroe III DM. The action of high-dose factor VIIa in a cell-based model hemostasis. Disease A Month 2003;49:1-7.

  3. Friederich PW, Levi M, Bauer KA, Vlasuk GP, Rote WE, Breederveld D, et al. Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. Circulation 2001;103:2555-2559.

  4. Hendrick HG, Meijer K, de Wolf JT, Klompmaker IJ, Porte RJ, de Kam PJ, et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation. 2001;71:402-405.

  5. Hendriks HG, Meijer K, de Wolf JT, Porte JR, Klompmaker IJ, Lip H, et al. Effects of recombinant activated factor VII on coagulation measured by thromboelastography in liver transplantation. Blood Coagul Fibrinolysis 2002;13:309-313.

  6. Zylberberg A. Probabilidad y Estadística. 1ª. ed. Nueva Librería. Buenos Aires, Argentina. 2005.

  7. Spiegel M. Estadistica. 1a. ed. McGraw-Hill, México. 1970.

  8. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-1377.

  9. Gropper MA. Evidence Based Management of critically ill patients, analysis and implementation. Anest Analg 2004;99:566-572.

  10. Monroe DM, Hoffman M, Oliver JA, Robert HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. J Haematol 1997;99:542-547.

  11. He S, Blomback M, Ekman GJ, Hedner U. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haem 2003;1:1215- 1219.

  12. Veldman A, Hoffman M, Ehrenforth S. New Insights into the Coagulation System and Implication for New Therapeutic Options recombinant Factor VIIa. Curr Med Chem 2003:10:797-811.

  13. O’Connell NM, Perry DJ, Hodgson AJ, O’Shaughnessy DF, Laffan MA, Smith OP. Recombinant FVIIra in the management of uncontrolled hemorrhage. Transfusion 2003;43:1711-1716.

  14. Dutton PR, McCunn M, Hyder M, D’Angelo M, O’Connor J, Hess JR, et al. Factor VIIa for Correction of Traumatic Coagulopathy. J Trauma 2004;57:709-719.

  15. Martinowitz U, Kenet G, Segal E, Luboshitz J, Lubetsky A, Ingersley J, et al. Recombinat Activated Factor VII for Adjunctive Hemorrhage Control in Trauma. J Trauma 2001;51;431-439.

  16. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999;354:1879-1885.

  17. Lin J, Hanigan WC, Tarantino M, Wang J. The use of recombinant factor VII to reverse warfarin induced anticoagulation in patients with haemorrhages in the central nervous system: preliminary findings. J Neurosurg 2003;98:737-740.

  18. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage. N Engl J Med 2005;352:777-785.

  19. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: A systematic review. Crit Care Med 2005;33:883-890.

  20. Enomoto MT, Thorborg P. Emerging off- label Uses for Recombinant Activated Factor VII: Grading the Evidence. Crit Care Clin 2005;21:611-632.

  21. Bosch J, Thabut D, Bendtsen F, D’Amico G, Albillos A, González A, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004;127:1123-1130.

  22. Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002;137:884-888.

  23. Sorensen B, Johansen P, Nielsen GL, Sorensen JC, Ingerslev J. Reversal of the international normalized ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis 2003;14:469-477.

  24. Park P, Fewel ME, Garton HJ, Thompson BG, Hoff JT. Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophilic neurosurgical patients. Neurosurgery 2003;53:34-38.

  25. Segal S, Shemesh IY, Blumenthal R, Yoffe B, Laufer N, Erza Y, et al. Treatment of obstetric haemorrhage with recombinant activated factor VII (rFVIIa). Arch Gynecol Obstet 2003;268:266-267.




2020     |     www.medigraphic.com